Lumos Pharma Stock Book Value Per Share
| LUMO Stock | USD 4.30 0.02 0.46% |
Lumos Pharma fundamentals help investors to digest information that contributes to Lumos Pharma's financial success or failures. It also enables traders to predict the movement of Lumos Stock. The fundamental analysis module provides a way to measure Lumos Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lumos Pharma stock.
| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.35 | 3.18 | |
| Tangible Book Value Per Share | 3.35 | 3.18 |
Lumos | Book Value Per Share |
Lumos Pharma Company Book Value Per Share Analysis
Lumos Pharma's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Lumos Pharma Book Value Per Share | 0.57 X |
Most of Lumos Pharma's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lumos Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Lumos Book Value Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Lumos Pharma is extremely important. It helps to project a fair market value of Lumos Stock properly, considering its historical fundamentals such as Book Value Per Share. Since Lumos Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lumos Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lumos Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
Lumos Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, the book value per share of Lumos Pharma is about 0.568 times. This is 133.41% lower than that of the Biotechnology sector and 100.23% lower than that of the Health Care industry. The book value per share for all United States stocks is 99.97% higher than that of the company.
Lumos Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lumos Pharma's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lumos Pharma could also be used in its relative valuation, which is a method of valuing Lumos Pharma by comparing valuation metrics of similar companies.Lumos Pharma is currently under evaluation in book value per share category among its peers.
Lumos Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Lumos Pharma from analyzing Lumos Pharma's financial statements. These drivers represent accounts that assess Lumos Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Lumos Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 366.1K | 242.0M | 57.8M | 30.2M | 25.9M | 39.6M | |
| Enterprise Value | (89.0M) | 143.7M | (36.5M) | (25.5M) | (8.6M) | (9.0M) |
Lumos Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lumos Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lumos Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Lumos Fundamentals
| Return On Equity | -1.73 | ||||
| Return On Asset | -0.7 | ||||
| Operating Margin | (10.52) % | ||||
| Current Valuation | 24.02 M | ||||
| Shares Outstanding | 8.65 M | ||||
| Shares Owned By Insiders | 32.69 % | ||||
| Shares Owned By Institutions | 24.27 % | ||||
| Number Of Shares Shorted | 89.51 K | ||||
| Price To Earning | (2.37) X | ||||
| Price To Book | 7.60 X | ||||
| Price To Sales | 16.87 X | ||||
| Revenue | 2.05 M | ||||
| Gross Profit | 1.52 M | ||||
| EBITDA | (36.57 M) | ||||
| Net Income | (34.03 M) | ||||
| Cash And Equivalents | 79.51 M | ||||
| Cash Per Share | 9.49 X | ||||
| Total Debt | 585 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 17.59 X | ||||
| Book Value Per Share | 0.57 X | ||||
| Cash Flow From Operations | (31.09 M) | ||||
| Short Ratio | 0.80 X | ||||
| Earnings Per Share | (4.28) X | ||||
| Price To Earnings To Growth | (0.15) X | ||||
| Target Price | 4.25 | ||||
| Number Of Employees | 30 | ||||
| Beta | 0.33 | ||||
| Market Capitalization | 37.19 M | ||||
| Total Asset | 40.64 M | ||||
| Retained Earnings | (161.52 M) | ||||
| Working Capital | 33.01 M | ||||
| Current Asset | 115.78 M | ||||
| Current Liabilities | 14.4 M | ||||
| Net Asset | 40.64 M |
About Lumos Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lumos Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lumos Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lumos Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Lumos Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lumos Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lumos Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lumos Pharma Stock: Check out Lumos Pharma Piotroski F Score and Lumos Pharma Altman Z Score analysis. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.28) | Revenue Per Share 0.27 | Quarterly Revenue Growth 102.714 | Return On Assets (0.70) | Return On Equity (1.73) |
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.